Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Enzyme inhibitor
JNJ-42165279
Другие языки:

    JNJ-42165279

    Подписчиков: 0, рейтинг: 0
    JNJ-42165279
    JNJ-42165279 Structure.svg
    Clinical data
    ATC code
    • None
    Legal status
    Legal status
    Identifiers
    • N-(4-Chloropyridin-3-yl)-4-[(2,2-difluoro-1,3-benzodioxol-5-yl)methyl]piperazine-1-carboxamide
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    Chemical and physical data
    Formula C18H17ClF2N4O3
    Molar mass 410.81 g·mol−1
    3D model (JSmol)
    • c3c1OC(F)(F)Oc1ccc3CN4CCN(CC4)C(=O)Nc2cnccc2Cl
    • InChI=1S/C18H17ClF2N4O3/c19-13-3-4-22-10-14(13)23-17(26)25-7-5-24(6-8-25)11-12-1-2-15-16(9-12)28-18(20,21)27-15/h1-4,9-10H,5-8,11H2,(H,23,26)
    • Key:YWGYNGCRVZLMCS-UHFFFAOYSA-N

    JNJ-42165279 is a drug developed by Janssen Pharmaceutica which acts as a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC50 of 70 nM. It is described as a covalently binding but slowly reversible selective inhibitor of FAAH. JNJ-42165279 is being developed for the treatment of anxiety disorders and major depressive disorder. Clinical development has progressed as far as Phase II human trials with two studies in patients with mood disorders registered in ClinicalTrials.gov.

    In early 2016, a trial with a different FAAH inhibitor — Bial's BIA 10-2474 — resulted in a series of severe adverse events, including a death. In response, Janssen announced that it was temporarily suspending dosing in its two Phase II clinical trials with JNJ-42165279, describing the decision as "precautionary measure follows safety issue with different drug in class". Janssen was emphatic that no serious adverse events had been reported in any of the clinical trials with JNJ-42165279 to date. The suspension is to remain in effect until more information is available about the BIA 10-2474 study. As of 2018, the trials had resumed.

    See also


    Новое сообщение